Selank: Sequence, Origins, And Receptor Research
Selank is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro) derived from the endogenous immunomodulatory peptide tuftsin. Tuftsin (Thr-Lys-Pro-Arg) is a tetrapeptide fragment of the Fc region of immunoglobulin G that influences immune cell function, and Selank extends this sequence with an additional tripeptide Pro-Gly-Pro to improve stability. The structural modification was designed to extend the peptide half-life in vivo while preserving the core bioactivity studied in tuftsin research.
In animal model research, Selank has been studied primarily for anxiolytic-like effects in behavioral paradigms such as the elevated plus maze and the open-field test. These models measure indices of exploratory behavior and avoidance that are interpreted as proxies for anxiety-related states in rodents. Selank research in these paradigms has been associated with reports of reduced anxiety-like behavior without the sedation or motor impairment associated with benzodiazepines, making it of interest for dissecting anxiolytic mechanism research.
At the molecular level, Selank research has examined its effects on GABA receptor modulation, enkephalin system interactions, and serotonin transporter activity. The precise receptor through which Selank exerts its primary effects remains under investigation, which is why it is categorized as a research compound rather than a compound with a defined, single molecular target.
Semax: ACTH Fragment, Neuroprotection, And BDNF Research
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the adrenocorticotropic hormone (ACTH) sequence, specifically from the ACTH(4-7) fragment with a C-terminal Pro-Gly-Pro extension. The ACTH(4-7) fragment (Met-Glu-His-Phe) is the core sequence, and the extension, identical to the one used in Selank, provides metabolic stability.
ACTH(4-10) and related fragments have been studied for decades for their effects on learning and memory in animal models, independent of their corticotropic activity. Semax was developed as a simplified, stable analog of this fragment for research investigation of cognitive and neuroprotective mechanisms. In cell culture and animal studies, Semax research has focused on BDNF upregulation, nerve growth factor (NGF) modulation, and neuroprotection in models of ischemic injury and oxidative stress.
BDNF (brain-derived neurotrophic factor) is a member of the neurotrophin family that supports neuronal survival, synaptic plasticity, and cognitive function. Research showing that Semax upregulates BDNF mRNA and protein in cultured neural cells and in rodent brain tissue has been a key driver of interest in the compound as a nootropic and neuroprotective research tool.
- Semax is based on ACTH(4-7) with a Pro-Gly-Pro stability extension.
- BDNF upregulation is the most reported mechanistic finding in Semax research.
- Neuroprotective effects have been studied in ischemia and oxidative stress models.
- Cognitive behavioral research in animal models includes maze performance and avoidance paradigms.
Comparative Research Context
Selank and Semax are often co-referenced in the nootropic peptide research literature because they share a common structural element (the Pro-Gly-Pro extension), were developed in the same research institution, and are both administered intranasally in the preclinical literature. Despite these similarities, their primary research contexts differ: Selank is more closely associated with anxiolytic and immune-modulatory research, while Semax is more closely associated with neurotrophic and cognitive research.
A point of distinction for in vitro research is that both peptides are typically studied in neural cell models including primary cortical neuron cultures, PC12 cells (a model of sympathetic neuron differentiation), and astrocyte preparations. The choice of cell model affects the endpoints available and the interpretation of BDNF or neurotrophic signaling data, so this should be carefully documented in research protocols.
Both compounds have been studied using intranasal delivery routes in preclinical work, which is relevant to their pharmacokinetic characterization but does not alter their Research Use Only status. All research on Selank and Semax is framed around laboratory investigation, not clinical application.
Research Use Only Status And Evidence Considerations
Selank and Semax are Research Use Only compounds not approved by the FDA or EMA for human use in Western regulatory contexts. Both have been registered in Russia (Selank as an anxiolytic, Semax for stroke and neurological rehabilitation), but those registrations do not alter the RUO status of material supplied for laboratory research outside those jurisdictions.
The evidence base for both compounds is weighted toward animal studies and a limited number of Russian clinical trials, with less independent replication in Western academic settings. Researchers evaluating these compounds should apply standard evidence-evaluation practices, examining study type, effect size, and replication status before drawing conclusions from the literature.
Research Use Only: This guide is informational and describes research-context handling of compounds intended strictly for in vitro laboratory research. Products are not for human or animal consumption, ingestion, or injection, and are not FDA-approved. Nothing here is medical, clinical, or dosing advice.